Drug Profile
Ubidecarenone - Berg Pharma
Alternative Names: API-31510; BP 31510; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; CoQ10 - Cytotech; Ubiquinone injectable nanosuspensionLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Cytotech Labs
- Developer Berg Pharma; National Cancer Institute (USA); Stanford Cancer Institute; Stanford University; University of Miami
- Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
- Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma; Pancreatic cancer; Squamous cell cancer
- Phase I/II Glioma
- Phase I Epidermolysis bullosa
- No development reported Solid tumours
- Discontinued Basal cell cancer; Leukaemia; Lung cancer; Wounds
Most Recent Events
- 18 Jan 2024 Updated efficacy data from a phase-II trial in Pancreatic cancer released by Berg Pharma
- 14 Nov 2023 Ubidecarenone phase I development in Epidermolysis-bullosa is ongoing in USA (BPG Bio website; November 2023)
- 14 Nov 2023 BPGbio plans a phase IIb trial for Sacropenia (IV) (BPGbio website, November 2023)